|Videos|May 20, 2022

Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma

In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery NCT03438708) clinical trial,” which he presented at the 2022 AUA Annual Meeting (LBA01-08).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME